Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.vbshilpa.com | |
Market Cap | 3,906.09 Cr. | |
Enterprise Value(EV) | 4,536.53 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 6.99 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 64.10 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 28.15 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 209.93 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 2.13 | Calculated using Price: 448.00 |
Dividend Yield | 0.24 | Period Ending 2021-03 |
No. of Shares Subscribed | 8.68 Cr. | 86,801,898 Shares |
FaceValue | 1 | |
Company Profile | ||
Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications. The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh. Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success. Being proactive in approach, the company continually seeks out enquiry’s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities. Product range of the company includes: Oncology AP's
General APIs
PRODUCTS UNDER DEVELOPMENT (Oncology)
NUTRITIONAL SUPPLEMENTS
DRUG INTERMEDIATES
Awards & Achievements:
|
1 Day |
|
+3.48% |
1 Week |
|
+6.30% |
1 Month |
|
-4.88% |
3 Month |
|
+5.61% |
6 Month |
|
-20.09% |
1 Year |
|
-13.16% |
2 Year |
|
+21.08% |
5 Year |
|
-34.47% |
10 Year |
|
+407.13% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 15.93 | 20.98 | 15.40 | 17.92 | 13.60 | 10.62 | 10.30 | 12.26 | 10.54 | |
Return on Capital Employed (%) | 15.04 | 20.48 | 17.90 | 19.90 | 15.91 | 11.71 | 11.05 | 12.41 | 10.82 | |
Return on Assets (%) | 9.64 | 12.23 | 9.18 | 11.58 | 9.20 | 7.41 | 7.56 | 8.61 | 6.39 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
Shh. Funds | 320 | 396 | 547 | 639 | 987 | 1,085 | 1,198 | 1,329 | 1,479 | 1,822 | |
Non Curr. Liab. | 99 | 105 | 154 | 67 | 251 | 153 | 167 | 257 | 568 | 453 | |
Curr. Liab. | 124 | 167 | 189 | 222 | 237 | 266 | 253 | 411 | 602 | 612 | |
Minority Int. | 9 | 10 | 14 | 2 | -3 | -5 | -8 | -8 | -11 | -11 | |
Equity & Liab. | 551 | 678 | 905 | 931 | 1,472 | 1,499 | 1,610 | 1,989 | 2,638 | 2,876 | |
Non Curr. Assets | 339 | 444 | 577 | 577 | 742 | 827 | 1,065 | 1,365 | 1,720 | 1,988 | |
Curr. Assets | 212 | 234 | 328 | 354 | 730 | 672 | 545 | 624 | 918 | 887 | |
Misc. Exp. not W/O | 0 | 0 | 0 | ||||||||
Total Assets | 551 | 678 | 905 | 931 | 1,472 | 1,499 | 1,610 | 1,989 | 2,638 | 2,876 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
Net Sales | 371 | 571 | 614 | 716 | 779 | 789 | 733 | 908 | 901 | 1,146 | |
Other Income | 5 | 9 | 7 | 11 | 29 | 33 | 16 | 22 | 40 | 14 | |
Total Income | 376 | 581 | 621 | 728 | 809 | 821 | 749 | 930 | 941 | 1,160 | |
Total Expenditure | -302 | -455 | -487 | -556 | -618 | -638 | -579 | -693 | -729 | -942 | |
PBIDT | 75 | 125 | 133 | 171 | 191 | 184 | 170 | 237 | 212 | 218 | |
Interest | -2 | -4 | -4 | -4 | -3 | -3 | -4 | -5 | -22 | -41 | |
Depreciation | -15 | -23 | -21 | -23 | -31 | -37 | -42 | -44 | -54 | -80 | |
Taxation | -10 | -20 | -35 | -36 | -42 | -34 | -26 | -33 | -49 | -42 | |
Exceptional Items | 0 | -3 | 0 | -2 | -5 | 20 | 61 | 9 | |||
PAT | 47 | 75 | 73 | 106 | 111 | 110 | 118 | 155 | 148 | 64 | |
Minority Interest | 0 | 1 | 1 | 4 | 3 | 2 | 3 | 2 | 2 | 0 | |
Share Associate | -2 | -6 | -7 | -8 | 0 | -2 | -4 | ||||
Other Related Items | |||||||||||
Consolidated Net Profit | 47 | 76 | 74 | 108 | 108 | 105 | 112 | 156 | 148 | 61 | |
Adjusted EPS | 6 | 10 | 10 | 14 | 13 | 13 | 14 | 19 | 18 | 7 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 57 | 44 | 70 | 69 | 129 | 37 | 45 | 147 | 124 | 47 | |
Cash Fr. Inv. | -152 | -95 | -49 | -195 | -109 | -262 | -9 | -196 | -290 | -404 | |
Cash Fr. Finan. | 10 | 66 | -28 | 136 | -20 | 313 | -61 | 10 | 176 | 436 | |
Net Change | -86 | 15 | -7 | 10 | 0 | 88 | -25 | -39 | 10 | 79 | |
Cash & Cash Eqvt | 2 | 17 | 9 | 18 | 6 | 100 | 74 | 34 | 44 | 123 |
Fri, 27 May 2022
Proceedings Of NCLT Convened Meeting Of Equity Shareholders Trade Creditors And Secured Creditors In reference to the captioned subject we hereby wish to inform that the NCLT Convened Meeting of the Equity Shareholders Trade Creditors and Secured Creditors of Shilpa Medicare Limited on 27 May 2022.please find herewith the enclosed summary of the proceedings of meeting of the Equity Shareholders Trade Creditors and Secured Creditors of the Company convened as per the directions of NCLT as Annexures I II and III respectively. |
Wed, 25 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication of Audited Financial Results for the quarter and year ended 31 March 2022 |
Mon, 23 May 2022
Appointment of Company Secretary and Compliance Officer Appointment of Company Secretary & Compliance Officer |
Fri, 27 May 2022 |
|
|
|
|
Thu, 26 May 2022 |
|